Newsfeeds - Spark Newswire

1 minute read

Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program

Today, 3:42 AM

Gilead Sciences Inc (NASDAQ:GILD) and Jounce Therapeutics Inc (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to…

GILD

1 minute read

Cal-Maine Foods, Kala Pharmaceuticals And 3 Stocks To Watch Heading Into Wednesday

By Lisa Levin

Today, 3:42 AM

With US stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

CALM

3 minute read

Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket

By Lisa Levin

Today, 3:42 AM

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday.

ABCL

1 minute read

Jounce Therapeutics Presents INNATE Phase 1 And SELECT Clinical Trial Data At The European Society Of Medical Oncology Immuno-Oncology Annual Congress

By Benzinga Newsdesk

Today, 3:42 AM

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines

JNCE